Rheumatoid arthritis coexisting with ankylosing spondylitis: A report of 22 cases with delayed diagnosis

Yuanyuan Zhang, MMSc, Bo Feng, MMSc, Jing Dong, MD, Yanyan Zhong, MMSc, Liqin Wang, MMSc, Lei Zhao, MMSc

Abstract

Coexisting rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in the same patient is often thought to be rare, and thus misdiagnosis is common. The aim of our study was to describe the main characteristics of RA coexisting with AS in patients with delayed diagnoses and improve awareness of the disease association.

Between 2012 and 2018, data from 22 patients who had RA and AS (RA/AS) were retrospectively reviewed. All patients had a history of delayed diagnosis for RA or AS. The clinical features and radiographic changes of RA and AS patients were obtained at baseline and after 2 years. Disease activity score 28 (DAS28) or bath ankylosing spondylitis disease activity index (BASDAI) were used as outcome measures. The mean age at the time of diagnosis of RA/AS was 51.8 years, while the mean duration of diagnostic delay was 5.5 years. Middle-aged women were the most common subgroup among the RA/AS cohort. The common clinical manifestations were systemic, symmetric, peripheral, and axial arthritis. The erythrocyte sedimentation rate and C-reactive protein levels in RA/AS patients were elevated at the time diagnosis of RA/AS. The typical radiologic changes for the 2 diseases coexisted in RA/AS patients. The DAS28 and BASDAI scores at the 2-year follow-up evaluation were lower than the initial assessment.

Coexisting RA and AS is often misdiagnosed for many years; a lack of recognition of RA and AS together is one of the most common reasons. Systemic, symmetric, peripheral, and axial arthritis in middle-aged women were the most frequent presentations at onset.

Abbreviations: AS = ankylosing spondylitis, BASDAI = bath ankylosing spondylitis disease activity index, DAS28 = disease activity score 28, RA = rheumatoid arthritis.

Keywords: ankylosing spondylitis, coexistence, diagnosis, rheumatoid arthritis

1. Introduction

Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are common autoimmune rheumatic diseases that have obvious distinctions in genetic peculiarities, clinical manifestations, imaging features, and serologic markers. According to previous reports, the 2 diseases rarely coexist in the same patient[1-3]; however, we found that patients with coexisting RA and AS (RA/AS) are not rare in the clinical setting. Thus, it is possible that a large number of these patients are overlooked by clinicians. To improve the early diagnosis and treatment, we retrospectively analyzed 22 RA/AS patients with delayed diagnoses over the past 7 years.

2. Methods

2.1. Patients

From January 2012 to December 2018 patients who were diagnosed with RA and AS at the Affiliated Hospital of Qingdao University were identified using a computer retrieval system. Patients who had complaints of a delayed diagnosis for either disease were collected. The protocol was reviewed and approved by the local Ethics and Research Committees of the Affiliated Hospital of Qingdao University.

2.2. Inclusion criteria

According to medical records, RA was diagnosed using the 1987 American Rheumatism Association classification criteria[4] and AS was diagnosed using the 1984 revised New York standard.[5] Patients with psoriasis or a family history were excluded from this study. Patients with RA associated with other connective tissue diseases were also excluded.
2.3. Clinic and laboratory data
Clinical data, including age, sex, duration of disease, family history, number of swollen and tender joints, and extra-articular manifestations (EAMs), were collected from medical records. EAMs included rheumatic nodules, rheumatic vasculitis, xerophthalmia, iridocyclitis, infection, lung involvement, cardiac involvement, nervous system lesions, and anemia.[6–8] The laboratory examination included a complete blood count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, rheumatoid factor (RF) titer, and anti-cyclic citrullinated peptide (anti-CCP), anti-nuclear (ANA), and human leukocyte antigen-B 27 (HLA-B27) antibody titers. Use of disease-modifying anti-rheumatic drugs (DMARDs) and biological agents was recorded.

2.4. Imaging
Two imaging experts concurrently reviewed the imaging x-ray data of the hands and wrists and computed tomography (CT) data of the sacroiliac joints (SIJs) and lungs from the 22 patients. Scores of space narrowing and bone erosion were obtained at baseline and after 2 years according to the Sharp method.[9,10] Radiographs of the SIJ obtained at baseline and after 2 years of follow-up were scored according to the modified New York criteria grading system (grade 0–4)[11], however, we did not perform a statistical analysis for imaging changes due to the small sample size.

2.5. Follow-up and assessment
The disease activity score (DAS28) score and the Bath ankylosing spondylitis disease activity index (BASDAI) were used to assess disease activity.[12,13] DAS28 scores were assessed at the first rheumatology visit and after 2 years of follow-up.

2.6. Statistical analysis
All statistical analyses were performed with SPSS (version 25.0; IBM, Armonk, NY). The mean ± standard deviation was used to represent the normal distribution of metrological data and medians were used to represent non-normally distributed data. Frequencies and rates were used to represent count data.

3. Results
3.1. Demographics and laboratory data
Thirty patients who were diagnosed with RA and AS were identified. Twenty-two patients (73.3%) who had history of delayed diagnosis for either disease were included in this study. The mean age of RA/AS patients was 51.80 ± 18.20 years. The mean duration of diagnostic delay was 5.5 years. The male-to-female ratio was 1:2.14. At the time of the initial diagnosis of RA/AS, the average leukocyte count, hemoglobin concentration, platelet count, ESR, CRP level, and RF and anti-CCP antibody titers were 8.18 ± 2.84 (×10^9/L), 118.00 ± 22.00 (g/L), 336.00 ± 107.00 (×10^9/L), 81.25 ± 97.20 (mm/60min), 67.70 ± 65.74 (mg/L), 114.08 ± 193.10 (IU/mL), and 148.60 ± 185.33 (U/mL), respectively. The positive titers for HLA-B27 and ANA antibody titers were 57.10% (12/21), and 40.90% (9/22), respectively (Table 1).

3.2. Imaging
We quantified the hand and double wrist x-ray grading (0–5) and SIJ x-ray and CT grading (0–5) of patients with coexisting RA and AS. The typical radiologic changes of the coexisting diseases in 2 RA/AS patients are shown in Fig. 1. Imaging classification is shown in Table 2.

3.3. Changes in disease activity after 2 years of follow-up
The mean values of the DAS28 and BASDAI scores at the initial rheumatology diagnosis were 5.98 ± 0.94 and 9.13 ± 0.59, respectively. After 2 years of follow-up, the mean values were 4.04 ± 1.25 and 5.44 ± 1.12, respectively. The DAS28 and BASDAI scores of the 2-year follow-up were lower than the first assessment (Table 1). One patient was lost to follow-up and 1 patient died.

3.4. Treatment
The 22 patients were treated with at least one of the DMARDs during the 2-year follow-up. Methotrexate was most commonly used (14/22), followed by sulfasalazine (12/22), leflunomide (10/22), hydroxychloroquine (6/22), and thalidomide (3/22). Notably, 18 of 20 patients used at least one TNF inhibitor for >6 months including etanercept, adalimumab, and infliximab.

4. Discussion
RA and AS occur with comparable frequencies (0.30%–1.50%) in the general population. The probability for co-occurrence of RA and AS in the same patient has been reported to range from 1/50,000 to 1/100,000.[14,15] However, the rarely described phenomenon of RA and AS coexistence may be more widespread than previously thought because of some uncertain genetically conditions or administered therapy which can mask the symptoms of one of the diseases.[11] In our study we identified 30 RA/AS patients; 22 (73.3%) patients had a history of delayed diagnosis for RA or AS. The mean duration of diagnostic delay was 5.5 years. This implies that misdiagnosis or diagnosis delay may be another reason for the rarely described phenomenon of
coexistence of the 2 diseases. In the context of the current study, there might be several reasons for the diagnostic delay. First, some AS patients have no prominent axial symptoms; thus, peripheral arthritis could lead to a diagnosis of RA. Similarly, RA patients are seldom screened for HLA-B27 antibodies or undergo a SIJ x-ray examination. Third, some RA/AS patients were RF- and HLA-B27-negative, which is often overlooked by clinicians. Our study suggested that vigilance and careful clinical examinations that include essential tests should facilitate early recognition in patients with these 2 chronic conditions. Particular attention should be paid to RA patients with symptoms of typical axial spondyloarthritis, as well as AS patients with symptoms of peripheral joint arthritis. AS is more commonly seen in young male adults; however, our study showed that most RA/AS patients with a delay in diagnosis were middle-aged women. This finding showed that there is a need for an awareness of coexisting RA and AS in middle-aged women.

One of the common features of the 2 diseases is the increase of inflammatory markers like CRP and ESR, which are both elevated significantly in our patients. At the same time, HLA-B27 and RF, 2 markers that could have distinguished the 2 diseases, exist simultaneously in 12 patients. According to previous studies, one-half of AS patients have peripheral joint involvement at some stage of the disease that may be indistinguishable from RA, both clinically and pathologically. Similarly, patients with advanced RA can have bony fusion of the cervical spine and SIJs that is radiologically indistinguishable from AS. Our study demonstrated that the typical radiologic changes of the 2 diseases can coexist. For example, as seen in 10 patients, bilateral sacroiliac and lumbar vertebral damage, including “bamboo” changes, can coexist with symmetric small joint damage. The primary manifestation based on lung computed tomography in the RA/AS group was pulmonary interstitial fibrosis. Other manifestations included pulmonary infections, lung fibrous foci,
We assessed the DAS28 and/or BASDAI score(s) at the time of onset. We found that after 2 years of therapy, the DAS28 and BASDAI scores of RA/AS patients were lower than the first assessment. All patients had used at least one TNF inhibitor and most patients had used at least one DMARDs and most patients had used at least one TNF inhibitor for >6 months, which might be one explanation for the low disease activity after 2 years of follow-up. The prognosis of our cases is overall good, however, further study is warranted to evaluate the prognosis of this combination compared with the individual disease entities.

The shortcomings of this study were the small number of recruited patients and the retrospective method design. Imaging and treatment information was relatively incomplete. Factors responsible for diagnostic delay like late reporting of symptoms or inadequate imaging have not been further investigated. Long-term or prospective studies are needed for the diagnosis and treatment of RA/AS patients.

In conclusion, the diagnosis of coexisting RA and AS is often delayed. This study encourages rheumatologists to consider RA/AS as a possible diagnosis in patients with both peripheral and axial arthritis. Systemic, symmetric, peripheral, and axial arthritis in middle-aged women were the most frequent presentations at the time of onset.

| Table 2 |
| --- |
| Imaging classification of the patients with coexisting RA and AS. |
| **RA/AS (n=22)** |
| Sharp scores | 63.00±7.40 |
| X-ray classification of hand joint and wrist joint (%) | 0 level 11.00 (1/9) |
| | 2 level 33.00 (3/9) |
| | 3 level 22.00 (2/9) |
| | 4 level 33.00 (3/9) |
| CT classification of sacroiliac joint (%) | 2 level 13.60 (2/22) |
| | 3 level 72.70 (17/22) |
| | 4 level 13.60 (3/22) |
| Involvement of pulmonary by CT (%) | 66.40 (19/29) |
| Involvement of cervical vertebrae, thoracic vertebrae, or lumbar vertebrae (n of cases) | 2 |
| Involvement of shoulder or elbow joint (n of cases) | 8 |

AS = ankylosing spondylitis, CT = computed tomography, RA = rheumatoid arthritis.

pulmonary rheumatoid nodules, pleural thickening, emphysema, pleural effusions, and thoracic hardening; however, we did not perform a statistical analysis of the radiologic changes due to the small sample size. We found that after 2 years of therapy, the DAS28 and BASDAI scores of RA/AS patients were lower than the first assessment. All patients had used at least one of the DMARDs and most patients had used at least one TNF inhibitor for >6 months, which might be one explanation for the low disease activity after 2 years of follow-up.

The shortcomings of this study were the small number of recruited patients and the retrospective method design. Imaging and treatment information was relatively incomplete. Factors responsible for diagnostic delay like late reporting of symptoms or inadequate imaging have not been further investigated. Long-term or prospective studies are needed for the diagnosis and treatment of RA/AS patients.

In conclusion, the diagnosis of coexisting RA and AS is often delayed. This study encourages rheumatologists to consider RA/AS as a possible diagnosis in patients with both peripheral and axial arthritis. Systemic, symmetric, peripheral, and axial arthritis in middle-aged women were the most frequent presentations at the time of onset.

Author contributions

Conceptualization: Jing Dong.
Data curation: Yuanyuan Zhang, Bo Feng, Yanyan Zhong, Liqin Wang.
Formal analysis: Yuanyuan Zhang, Bo Feng, Lei Zhao.
Investigation: Jing Dong.
Methodology: Lei Zhao.

References

[1] Barczyńska TA, Ma GW, Zachowski P, et al. Coexistence of rheumatoid arthritis and ankylosing spondylitis. Reumatologia 2015;53:279–85.
[2] Borman P, Ayhan F, Okumus M. Coexistence of rheumatoid arthritis and ankylosing spondylitis. Clin Rheumatol 2011;30:1517–8.
[3] Guo YY, Yang LL, Cui HD, et al. Coexisting ankylosing spondylitis and rheumatoid arthritis: a case report with literature review. Chin Med J 2011;124:3430–2.
[4] Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheu-matism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
[5] Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–8.
[6] Cotoiu M, Cotoiu IM, Silosi I, et al. Extra-articular manifestations in rheumatoid arthritis. Maedica (Bucur) 2010;5:286–91.
[7] Rawla P. Cardiac and vascular complications in rheumatoid arthritis. Reumatologia 2019;57:27–36.
[8] Bendstrup E, Møller J, Kronborg-White S, et al. Interstitial lung disease in rheumatoid arthritis remains a challenge for clinicians. J Clin Med 2019;8:2038.
[9] Sharp JT, Young DY, Bluhm GB, et al. Many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 1985;28:1326–35.
[10] Brunynesteyn K, van der Heijde D, Boers M, et al. The Sharp van der Heijde method out-performed the Larsen/Scott method on the individual patient level in assessing radiographs in early rheumatoid arthritis. J Clin Epidemiol 2004;57:502–12.
[11] Mandl P, Supp G, Balak G, et al. Relationship between radiographic joint space narrowing, sonographic cartilage thickness and anatomy in rheumatoid arthritis and control joints. Ann Rheum Dis 2015;74:2022–7.
[12] Braun J, Baraliakos X. Imaging of axial spondyloarthritides including ankylosing spondylitis. Ann Rheum Dis 2011;70(suppl):97–103.
[13] Prevo ML, van’t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
[14] Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in AS: the bath ankylosing spondylitis disease activity index. J Rheumatol 1994;21:2286–91.
[15] Touboul P, Acquaviva PC. Coexisting rheumatoid arthritis and ankylosing spondylitis discussion of 3 cases with review of the literature. Clin Rheumatol 1995;14:554–60.
[16] Major P, Resnick D, Dalinka MK. Coexisting rheumatoid arthritis and ankylosing spondylitis. Am J Roentgenol 1980;134:1076–9.
[17] Rantapää-Das, Nordmark LG, Bjelle A. HLA-B27 and involvement of sacroiliac joints in rheumatoid arthritis. J Rheumatol 1984;11:27–32.
[18] Heuft-Dorenbosch L, Tubergen AV, Sporenberg A, et al. The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the bath ankylosing spondylitis disease activity index. Arthritis Rheum 2004;51:154–9.
[19] Lee JH, Jun JB, Jung S, et al. Higher prevalence of peripheral arthritis among ankylosing spondylitis patients. J Korean Med Sci 2002;17:669–73.
[20] Miehle W, Schattenkirchner M, Albert D, et al. HLA-DR4 in ankylosing spondylitis with different patterns of joint involvement. Ann Rheum Dis 1985;44:39–44.